Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Kluger, H. M., Stadler, W. M., … Sznol, M. (2015). Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Choueiri, Toni K., Mayer N. Fishman, Bernard Escudier, David F. McDermott, Harriet M. Kluger, Walter Michael Stadler, Jose Luis Perez-Gracia, et al. “Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Kluger HM, Stadler WM, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.

Choueiri, Toni K., et al. “Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman LJ, Fong L, Drake CG, Young TC, Chasalow SD, Ross-Macdonald P, Simon JS, Walker D, Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.